The FDA Just Cleared Elanco's New Screwworm Drug. The Stock Fell 5.9% Anyway

The FDA granted Elanco Animal Health emergency use authorization for CLiK Extra, a dicyclanil topical wound spray designed to prevent New World screwworm larvae infestations. The authorization covers application on or around wounds in sheep, cattle, goats, swine, and camelids, as well as several captive and captured wildlife species, including American bison, bighorn sheep, and Sonoran pronghorn — a broader species list than a typical livestock-only approval.

The product's scope matters more than it might first appear. CLiK Extra is a prevention tool, not a treatment: it stops screwworm larvae from infesting a wound in the first place, but it does not treat an infestation that has already taken hold. Producers dealing with active larvae still need a different product. That distinction is also why this is Elanco's third screwworm-related emergency authorization this year — CLiK Extra joins Negasunt Powder and Tanidil, which received their own emergency authorizations earlier in 2026, as part of a broader response to the screwworm threat rather than a single standalone product launch.

Despite the authorization being a genuine regulatory win, Elanco shares fell 5.9% the same day. A real approval moving a stock in the opposite direction of the headline is not unusual — it typically reflects the size of the news relative to the company's existing valuation, broader market conditions on the day, or investors treating an emergency authorization for a niche, geographically specific product (screwworm outbreaks are concentrated in specific US regions and Central America) as a smaller catalyst than the headline framing suggests.